FDA Approves Palynziq for Phenylketonuria

Share this content:
FDA Approves Palynziq for Phenylketonuria
FDA Approves Palynziq for Phenylketonuria

FRIDAY, May 25, 2018 (HealthDay News) -- Palynziq (pegvaliase-pqpz) has been approved by the U.S. Food and Drug Administration to treat phenylketonuria, or PKU.

Palynziq is a novel enzyme therapy for adult patients with PKU with uncontrolled blood phenylalanine (Phe) concentrations despite treatment. The drug's safety and effectiveness were evaluated in clinical studies involving patients with high concentrations of blood Phe. Statistically significant reductions in blood Phe concentrations (from pre-treatment baseline levels) were seen in patients treated with Palynziq.

The most common side effects of the enzyme substitution therapy were injection-site reactions, hypersensitivity reactions, joint pain, headache pruritus, nausea, dizziness, and abdominal pain. The drug's label warns of a less-common risk of life-threatening anaphylaxis, which the agency said most often occurred when the dosage was increased during the first year of treatment.

"This is a novel enzyme substitution therapy that helps address a significant unmet need in PKU patients who have been unable to control their blood Phe levels with current treatment options," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "This new approval demonstrates our commitment to approving advancements in treatment that will give patients living with PKU different options for care."

Palynziq is produced by BioMarin Pharmaceutical, based in Novato, Calif.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Progress in HIV Prevention Has Stalled in the United States

CDC: Progress in HIV Prevention Has Stalled in ...

Agency says effective HIV prevention, treatment not reaching those who could most benefit

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in Children

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in ...

All children with sustained unresponsiveness ingested concentrated and baked egg

Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk

Prenatal Vitamin Intake in Early Pregnancy May Cut ...

ASD risk down for children whose mothers took prenatal vitamins during first month of pregnancy

is free, fast, and customized just for you!




Already a member?

Sign In Now »